Hepatic Oncology · Published 2025-06-17 · DOI 10.1080/20450923.2025.2516994
Aims Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.Methods In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin.Results The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively.Conclusion The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC.Clinical trial registration www.chictr.org.cn identifier is ChiCTR-OOC-17014182.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →